Range of qualified people: CDEC reviewed the uncertainty in the number of individuals with moderately extreme to significant hemophilia B in Canada eligible for etranacogene dezaparvovec. Clinical specialists consulted by CADTH indicated that some people who are classified as owning gentle or average disease may have a serious bleeding phenotype, https://griffinvtmcq.blogpixi.com/36045223/the-definitive-guide-to-hemgenix